The Evolving Care of Diabetes
Models, managed care, and public health I n the beginning, there was an individual patient with diabetes and that patient's individual physician. The goal of diabetes care was pretty simple: to stave off the complications of the disease-diabetic ketoacidosis and hyperosmolar coma-in that patient. Down the street in one direction was the insurance company that paid the bills for care rendered, and down the street the other direction was the public health department that might have cared about the patient should he or she have developed tuberculosis or shigellosis. Not too long ago, this was the model for leading-edge diabetes care.
Lately, the discussion has turned to populations of diabetic patients, networks of physicians with measurable quality parameters, and preventable complications, as several issues have evolved simultaneously to create pressure toward change in the care of patients with diabetes. The clinical issues, driven by the results of the Diabetes Control and Complications Trial (DCCT) (1), have evolved from prevention of diabetic ketoacidosis and hyperosmolar coma to intensive glycemic control as a therapy for prevention of blindness, nephropathy, neuropathy and deaths attributable to diabetes many years from the present. Examination of these very different kinds of clinical concerns requires new tools. Care management issues have reflected the changes in the marketplace as traditional health insurance, "unmanaged care," is disappearing and people are increasingly entering managed care health plans: point of service (POS) plans and health maintenance organizations (HMOs). In managed care, an accrediting body, such as the National Committee for Quality Assurance (NCQA), performs regular reviews of plans and evaluates them along many dimensions, including their ability to improve patterns of care within their populations of patients (2) . This information is put into the marketplace by plan-specific measurements that result from these reviews being made available to the public through the NCQA homepage on the Internet. Measures of quality for diabetes care in the past (HEDIS 2.5 and HEDIS 3.0) have included the frequency of annual retinal examinations in patients with diabetes, but have not focused on the issue of tight control for a variety of clinical and coding reasons (3, 4) . The market is attempting to buy quality care, and the competition among managed care health plans is increasingly based on the ability of plans as private sector organizations to improve the health of the public whom they serve. In the public sector, public health departments are evolving, embracing a new educational role in chronic diseases such as diabetes and intervening proactively in a growing number of chronic diseases.
Eastman and colleagues (5,6) have performed a significant act by creating two tools that are useful in dissecting these issues. On one hand, they have collapsed the various complications of type II diabetes into a single base-case natural history model showing the multiplicity of complications; and on the other hand, they have developed the first of what I assume will be many interventional models examining the health impact of, in this case, tight glucose control on the development of these complications across the U.S. type II diabetic population under 75 years of age. There are three questions to answer when reviewing such models: do they answer an important question, do they appear to be valid, and what are the logical consequences of accepting or discarding them? Do models of the natural history of type II diabetes and of the benefits of tight control in this population answer important questions? Certainly these are critical questions. Diabetes affects over 13 million Americans; over 12 million have type II diabetes. While there are many clinical and epidemiological trials that have examined these patients a single issue at a time, the natural history model provides an opportunity to aggregate a variety of clinical complication issues-cardiovascular disease, retinopathy neuropathy, nephropathy, and life expectancy-together for a simultaneous analysis. This approach may be confusing at first to people who have dealt in the past primarily with the results of clinical trials that typically have a single primary hypothesis to examine. The issue of the benefits of tight control on microvascular complications in type I diabetes has been largely answered by the DCCT (1). One of the weaknesses of the model is that some of the coefficients are extrapolations of the benefits of tight control from the DCCT to a type II population; however, there are no comparably robust data on progression of type II diabetes with or without tight control. Despite its observational design, the U.K. Prospective Diabetes Study (UKPDS) (7) may yield different coefficients of progression of the disease over time, and when those data are available, the natural history model has the flexibility to incorporate them.
Do the models appear valid?
On review, the approach of the natural history model appears generally valid for the average health benefits to a type II diabetic population. In the intensive glycemic control model, there is a marginal analysis: the model describes a change in treatment pattern from one state to another. As a reality check for the assessment of the baseline case, a traditional insurance/preferred provider organization (PPO) claims dataset for a 12-month period in 1994-1995 was created. Of the 22,000 diabetic patients identified in this dataset, 80% did not have a claim paid for an HbA lc determination and only 8% had two or more tests. This seems a long way from the American Diabetes Association recommendation that the test be performed four times per year in all insulin-treated patients and as frequently as necessary in non-insulin-treated patients (8) . This disturbing fact suggests that unmanaged care health plans are far from systematically embracing American Diabetes Association recommendations with or without tight control as the standard of care. Of note is that one quality measure for diabetes care developed by the Foundation for Accountability (FACCT) is the percentage of HbA lc values that are above an agespecific threshold value (9) . This kind of approach might be prone to significant biases because of a low percentage of patients receiving the test, and while HbA lc is certainly not a specific marker for nearnormoglycemic control, it may be a quite specific marker for lack of near-normo-Editorial glycemic control. It should not be underestimated that moving diabetes patients through such a significant change in treatment as the implementation of tight control, which this article suggests will involve broad scale reeducating of providers about the treatment of diabetes or moving patients to a new provider, neither of which are easy options for health plan, patient, or provider.
What are the logical consequences of believing or discarding the models?
Because the natural history model answers a significant clinical question and has face validity and robust documentation, it is an important model to understand. The tight control model again answers a significant question; however, the model needs more assumptions to work than the first model. The real value is to put the model on one's own computer and adapt it to one's own population of interest: the population in one's care. I know the two topics to which I would next like to adapt the intervention model: blood pressure control and weight loss. Clearly, we live in a day when tight blood glucose control is a very popular issue because of the DCCT; and granted, there are benefits to be gained from tight glucose control in some patients with diabetes. As for blood pressure control, however, one concern is that the public health benefits to be obtained from tight blood pressure control in a population of patients with diabetes, while probably limited to macrovascular disease, may be even greater than the health benefits derived from tight blood glucose control. Examining the health status of the simulated population with slight changes in blood pressure would be of great interest in comparing the impact of these two parameters on longerterm complications. Finally, if you believe that type II diabetes is a condition of glucose intolerance largely resulting from obesity and that it carries with it an average 11.5 year decrement in life expectancy, then should there not be a way to link the initial diagnosis of type II diabetes with a significant weight loss program that might be able to reverse diabetes in some portion of the population? Granted this is a difficult path to follow, but it is the major question being systematically studied in the Diabetes Prevention Program (10); and aggressive weight loss with some of the newer pharmacological agents has been anecdotally reported to cure type II diabetes. Modeling the duration of these cures and the added longevity as a result of these cures should be of significant interest because normoglycemia attained through diet and exercise and the resulting weight loss should convey even greater health benefits than normoglycemia attained through injections of insulin.
For the millions of Americans with type II diabetes, the two models presented in this issue by Eastman and colleagues (5,6) represent a significant step in understanding the population-level issues in their diabetes care. The natural history model points to the complications of the disease, which result in over a decade of life lost by the average patient with diabetes. The normoglycemic control model points to one avenue for recapturing some of the lost years, while it simultaneously triggers thoughts about possibilities for other interventions that will result in dramatic benefits. While these benefits appear great, we should not underestimate the Herculean effort necessary for achieving them; they will require significant changes in how health care is provided across the nation. The time may be ripe for greater collaboration between diabetes patients, providers, managed care organizations, and public health departments to catalyze these changes to everyone's mutual advantage.
